Item – Thèses Canada

Numéro d'OCLC
458722133
Lien(s) vers le texte intégral
Exemplaire de BAC
Exemplaire de BAC
Auteur
Rowe, Elisabeth Jane,1980-
Titre
Can a growth hormone-derived peptide (AOD9604) prevent bone loss and fragility in a rat model of osteoporosis?.
Diplôme
M.A. Sc. -- University of Toronto, 2007
Éditeur
Ottawa :Library and Archives Canada = Bibliothèque et Archives Canada,[2007]
Description
2 microfiches
Notes
Includes bibliographical references.
Résumé
A synthetic human Growth Hormone (hGH) 16AA C-terminus peptide, AOD9604 (AOD, Tyr-hGH171-191), has been shown to modulate fat metabolism and is currently being developed as a novel weight-loss drug. However, intact hGH affects the skeleton as well as lipids. This current study identified similar skeletal effects with the hGH peptide and assessed the ability of AOD to prevent OVX-induced bone loss and fragility. Two different dosages (0.25mg/kg/day, AOD-0.25 and 0.5mg/kg/day, AOD-0.5) of orally administered drug were administered over a 12-wk period in the ovariectomized (OVX) rat. Bone mass, mechanics, material and structural parameters were assessed. Overall, we evidenced that both doses of AOD prevented OVX-induced fragility and bone loss in cortical bone. In trabecular bone, AOD-0.25 prevented OVX-induced fragility and attenuated bone formation and bone loss and these trabecular improvements were not evident with AOD-0.5.
ISBN
9780494273692
0494273690